CTD/DT 2026 Programme under CT.gov for Chiesi
Chiesi Farmaceutici S.p.A. has confirmed Maxer Consulting’s mandate to implement the 2026 Clinical Trial Disclosure and Data Transparency program, in line with current US regulations.
The CTD/DT activities require Maxer to upload the results of a series of clinical trials to ClinicalTrials.gov Protocol Registration and Result System in accordance with FDAAA 801 and Final Rule.
Maxer will also anonymise the documents accompanying the results (Protocol and Statistical Analysis Plan) attached to the studies that will be published on CT.gov.






Comments are closed.